Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: Results from the open-label Phase 1b/2 MISSION study
.
The 15th International Congress on Systemic Lupus Erythematosus and The 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023).
